Concise answers when you need the essentials, with deeper clinical context and transparent source links when the decision needs more scrutiny.
Search by active ingredient or familiar medicine name.
A topical treatment licensed for facial hirsutism in adult women. It slows hair growth rather than removing existing hair.
Efmoroctocog alfa is a recombinant factor VIII replacement with an Fc component that helps it remain in circulation longer. It treats and helps prevent bleeding in haemophilia A.
Eftrenonacog alfa is a recombinant clotting factor IX designed to remain in circulation longer. It treats and prevents bleeding in people of all ages with haemophilia B under specialist care.
Elacestrant is an oral selective oestrogen receptor degrader used as endocrine treatment for certain advanced breast cancers. In the UK, it is licensed on its own for postmenopausal women and men whose ER-positive, HER2-negative cancer has an activating ESR1 mutation and has progressed after specified previous endocrine treatment.
Eladocagene exuparvovec is an AAV2-based gene therapy for severe aromatic L-amino acid decarboxylase (AADC) deficiency. It delivers a functioning DDC gene to brain cells, enabling AADC enzyme expression and dopamine production.
Elafibranor treats adults with primary biliary cholangitis (PBC). It is used with ursodeoxycholic acid (UDCA) when UDCA has not worked well enough, or alone when UDCA cannot be tolerated.
A fixed-combination treatment for chronic hepatitis C, principally genotypes 1 and 4, used under specialist supervision.
Eletriptan hydrobromide is a prescription-only triptan for treating the headache phase of migraine attacks in adults, with or without aura. It does not prevent migraine.
A triple CFTR modulator for cystic fibrosis caused by eligible CFTR gene variants. In the UK, it is used with a separate ivacaftor product to improve the amount and function of CFTR protein at cell surfaces.
Eliglustat tartrate is an oral substrate-reduction treatment for Gaucher disease type 1. It reduces production of the fatty substance that accumulates in affected cells. Specialist testing is needed before treatment to assess how the body metabolises it.
Elotuzumab is a humanised monoclonal antibody used with other anti-myeloma treatments for previously treated multiple myeloma.
Elranatamab is a bispecific antibody cancer treatment that helps T cells recognise and destroy multiple myeloma cells. It is licensed for use alone in previously treated adults whose multiple myeloma has returned and is resistant to treatment.
Eltrombopag olamine is a thrombopoietin-receptor agonist that stimulates bone marrow to make more platelets. Specialists use it for selected people with low platelet counts or severe aplastic anaemia.
Emicizumab is a bispecific monoclonal antibody used to prevent or reduce bleeding in haemophilia A. It provides factor VIII-like activity and can work whether or not factor VIII inhibitors are present.
Empagliflozin is a prescription SGLT2 inhibitor that makes the kidneys remove more glucose and sodium in urine. In the UK, it is licensed for type 2 diabetes, symptomatic chronic heart failure and chronic kidney disease in specified age groups.
This fixed-dose tablet combines empagliflozin, an SGLT2 inhibitor, with linagliptin, a DPP-4 inhibitor. It is used in selected adults with type 2 diabetes to improve blood glucose control.
A fixed-dose tablet combining an SGLT2 inhibitor with metformin. Alongside diet and exercise, it improves blood glucose control in people with type 2 diabetes when metformin-based treatment is insufficient.
Emtricitabine is a nucleoside reverse-transcriptase inhibitor used with other antiretrovirals to treat HIV-1. It reduces viral replication but does not cure HIV and should not be used alone for treatment.
A fixed-combination antiretroviral treatment for HIV-1. It reduces viral replication and helps control viral load, but does not cure HIV.
A fixed-combination antiretroviral treatment for selected adults with HIV-1 whose viral load and resistance history meet product-specific criteria.
This combination contains two antiretroviral reverse-transcriptase inhibitors. It is used with other antiretrovirals to treat HIV-1 and, within its licensed population, as pre-exposure prophylaxis (PrEP). It does not cure HIV.
This fixed-combination tablet contains two reverse-transcriptase inhibitors. It is used with other antiretrovirals to treat HIV-1, or as pre-exposure prophylaxis (PrEP) for people confirmed HIV-negative who are at high risk of acquiring HIV.
This fixed combination contains two reverse-transcriptase inhibitors. It is used with other antiretrovirals to treat HIV-1 and, in people confirmed HIV-negative, as pre-exposure prophylaxis (PrEP) alongside other prevention measures.
This fixed-combination antiretroviral is licensed for HIV-1 treatment as part of combination therapy and as PrEP to reduce sexually acquired HIV-1 risk in people confirmed to be HIV-negative.
This antiviral tablet combines two reverse-transcriptase inhibitors. It is licensed with other antiretrovirals to treat HIV-1 and as pre-exposure prophylaxis (PrEP) for people confirmed HIV-negative.
In the selected licensed aqueous cream, emulsifying ointment is combined with paraffins and water to moisturise dry skin. It can also replace soap for washing.
This water-containing emollient cream contains emulsifying ointment and paraffins. It relieves dry skin symptoms and can replace soap, although it may irritate some people when left on the skin.
This paraffin-based ointment contains recognised emollient ingredients. It is licensed for pharmacists to prepare Aqueous Cream BP and Buffered Cream BP, not with its own clinical indication or treatment schedule.
Enalapril maleate is an ACE inhibitor that relaxes blood vessels. It is used for high blood pressure and heart failure; a specific orodispersible product is licensed for heart failure in children.
This tablet combines an ACE inhibitor with a thiazide diuretic. It treats essential hypertension not adequately controlled by enalapril alone, or replaces the same components in someone already stabilised on them separately. It is not licensed as initial treatment.
Encorafenib is a targeted anti-cancer treatment that blocks abnormal BRAF signalling. In adults, it is used with other treatments for certain BRAF-mutated melanomas, colorectal cancers and non-small cell lung cancers.
Enfortumab vedotin is an antibody–drug conjugate that targets Nectin-4 and delivers a cell-killing agent into cancer cells. It is used for certain bladder and urothelial cancers, either with pembrolizumab or alone after specified previous treatments.
Enoxaparin sodium is a low molecular weight heparin anticoagulant given by injection. It helps prevent new blood clots and stops existing clots becoming larger.
Entacapone is a COMT inhibitor used alongside levodopa in adults with Parkinson’s disease. It prolongs levodopa’s effect and may reduce end-of-dose wearing off. It does not control symptoms when taken alone.
Entecavir is a nucleoside analogue antiviral used mainly to treat chronic hepatitis B. It reduces viral replication, helping to limit ongoing liver damage, but does not prevent transmission.
Entecavir is a nucleoside analogue antiviral used to treat chronic hepatitis B. It reduces viral replication and helps limit continuing liver damage, but does not eliminate transmission risk.
Entrectinib is an oral targeted cancer treatment that blocks abnormal kinase signals produced by certain NTRK or ROS1 gene changes. It is used only when testing confirms a relevant alteration and the cancer meets specific licensing criteria.
Enzalutamide is an anti-androgen treatment for prostate cancer. It blocks hormone signals that can help prostate cancer cells grow.
Epcoritamab is a bispecific antibody that brings T cells into contact with CD20-positive lymphoma cells so the immune system can destroy them. It is a specialist treatment for adults with certain relapsed or treatment-resistant B-cell lymphomas, given by injection under the skin.
Ephedrine hydrochloride stimulates adrenergic pathways. UK-licensed tablets prevent or relieve asthma-related bronchospasm, while injections reverse low blood pressure caused by spinal or epidural anaesthesia.
Epinastine hydrochloride is an anti-allergic eye treatment licensed in the UK for symptoms of seasonal allergic conjunctivitis, including itchy, red, watery or swollen eyes.
Epirubicin hydrochloride is an anthracycline chemotherapy that damages the DNA of rapidly dividing cells. It is given in hospital into a vein for several cancers or directly into the bladder for certain superficial bladder cancers.
Eplerenone is an aldosterone-blocking treatment used alongside other treatments for certain adults with heart failure, including after some heart attacks.
Epoetin alfa is a laboratory-made version of erythropoietin, a hormone that signals bone marrow to make red blood cells. It treats selected types of symptomatic anaemia and can reduce blood transfusion needs in specific settings.
Epoetin beta is a manufactured form of erythropoietin, a hormone that stimulates bone marrow to make red blood cells. It is used to treat or prevent particular types of anaemia and is given by injection under specialist supervision.
Epoetin zeta is a biosimilar erythropoiesis-stimulating agent that acts like natural erythropoietin. It stimulates bone marrow to make red blood cells and treats selected causes of symptomatic anaemia or reduces transfusion requirements.
Epoprostenol sodium is an intravenous prostacyclin that widens blood vessels and reduces platelet aggregation. Specialist teams use it mainly for severe pulmonary arterial hypertension and, in certain emergencies, during haemodialysis when heparin is unsuitable.
Eprosartan mesilate is an angiotensin II receptor blocker that relaxes blood vessels and lowers blood pressure. The selected UK product is licensed for essential hypertension.
Eptacog alfa is a recombinant activated clotting factor VII. It helps form a clot at the bleeding site and is used under specialist supervision for certain bleeding disorders and severe bleeding after childbirth.
Eptacog beta is a recombinant activated human factor VII that helps blood clot without relying on factor VIII or IX. It is used for bleeding and around procedures in adults and adolescents with congenital haemophilia A or B and clinically important inhibitors.
Eptinezumab is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), which contributes to migraine. It prevents migraine in eligible adults but does not treat an attack already underway.
Eravacycline is an intravenous tetracycline antibiotic licensed for complicated infections within the abdomen in adults. It is a Reserve antibiotic, generally selected by specialist teams according to likely bacteria, susceptibility results and individual circumstances.
Erdosteine is an oral mucolytic that makes thick airway mucus less viscous and easier to clear. The selected UK product is licensed as an expectorant and for symptom relief during acute worsening of chronic bronchitis in adults.
Erenumab is a fully human monoclonal antibody that blocks the calcitonin gene-related peptide (CGRP) receptor. It prevents migraine in adults but does not treat an attack that has already started.
Ergocalciferol is vitamin D2, a fat-soluble vitamin that helps regulate calcium and phosphate. The selected injection treats consequences of poor vitamin D absorption caused by gastrointestinal, liver or biliary disease.
Ergometrine maleate is an ergot alkaloid that produces strong, sustained contraction of the womb. The injection is used under medical supervision during the third stage of labour and to control bleeding after birth.
Eribulin is cytotoxic chemotherapy that disrupts cancer-cell division. It is used in adults after previous treatment for certain advanced breast cancers or liposarcomas.
Eribulin mesylate is cytotoxic chemotherapy that disrupts structures needed for cancer-cell division. It is licensed for certain adults with previously treated advanced breast cancer or unresectable liposarcoma.
An oral targeted cancer treatment that blocks EGFR signalling. It is used for selected adults with advanced non-small-cell lung cancer and, with gemcitabine, metastatic pancreatic cancer.
Ertapenem is an intravenous carbapenem antibiotic that kills susceptible bacteria. It is used for selected infections requiring parenteral treatment and is a UK Reserve antibiotic.